Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Candel Therapeutics Inc
(NQ:
CADL
)
5.680
+0.370 (+6.97%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Candel Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
Candel Therapeutics Says One Dose Of CAN-3110 Shows Encouraging Responses In A Type Of Brain Cancer
May 19, 2023
Candel Therapeutics Inc (NASDAQ: CADL) announced new data from an ongoing phase 1 trial of its herpes simplex virus-1 (HSV-1) replication-competent viral immunotherapy candidate, CAN-3110, in patients...
Via
Benzinga
Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
May 19, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics: Q1 Earnings Insights
May 11, 2023
Via
Benzinga
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
May 11, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics's Return On Capital Employed Insights
March 31, 2023
Via
Benzinga
Candel Therapeutics Earnings Perspective: Return On Capital Employed
December 20, 2022
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
May 02, 2023
Via
Benzinga
Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO
May 02, 2023
From
Candel Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
April 21, 2023
Via
Benzinga
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer
April 17, 2023
Fast track designation has the potential to facilitate the development and expedite the U.S. FDA review of CAN-2409 plus valacyclovir and anti-PD1 antibodies in patients with stage III/IV non-small...
From
Candel Therapeutics
Via
GlobeNewswire
Why Tupperware Brands Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 10, 2023
Gainers PLx Pharma Inc. (NASDAQ: PLXP) gained 128.2% to $0.2399 after dropping over 13% on Thursday.
Via
Benzinga
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
March 30, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day
February 01, 2023
From
Candel Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
January 23, 2023
Via
Benzinga
Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference
January 12, 2023
From
Candel Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
December 16, 2022
Via
Benzinga
Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer
December 06, 2022
From
Candel Therapeutics
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2022
December 02, 2022
Via
Benzinga
Candel Therapeutics to Host Virtual R&D Day on December 6, 2022
November 29, 2022
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting
November 18, 2022
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma
November 11, 2022
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
November 10, 2022
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNO
November 07, 2022
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Upcoming Investor Conference Participation for November
November 01, 2022
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models
October 26, 2022
From
Candel Therapeutics
Via
GlobeNewswire
Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday
October 24, 2022
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) jumped 89.3% to close at $58.92 on Friday.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
October 21, 2022
Gainers
Via
Benzinga
Looking Into Candel Therapeutics's Recent Short Interest
October 21, 2022
Candel Therapeutics's (NASDAQ:CADL) short percent of float has risen 15.38% since its last report. The company recently reported that it has 57 thousand shares sold short, which is 0.3% of all regular...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
October 21, 2022
Gainers Statera BioPharma (NASDAQ:STAB) shares increased by 33.1% to $0.2 during Friday's pre-market session. The company's market cap stands at $10.4 million.
Via
Benzinga
Tesla, AT&T, AMD, Nvidia, Candel Therapuetics: What's Happening With These Top 5 Trending Stocks
October 20, 2022
Major U.S. indices closed in the red on Thursday as investors continued to digest higher Treasury yields as well as key earnings. The yield in the benchmark U.S. 10-year Treasuries topped 4.239%, a...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.